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Abstract
Background-: Mice deficient for the stable tubule only peptide (STOP) display altered dopaminergic
neurotransmission associated with severe behavioural defects including disorganized locomotor activity.
Endogenous morphine, which is present in nervous tissues and synthesized from dopamine, may contribute to
these behavioral alterations since it is thought to play a role in normal and pathological neurotransmission.
Results-: In this study, we showed that STOP null brain structures, including cortex, hippocampus, cerebellum and
spinal cord, contain high endogenous morphine amounts. The presence of elevated levels of morphine was
associated with the presence of a higher density of mu opioid receptor with a higher affinity for morphine in STOP
null brains. Interestingly, STOP null mice exhibited significantly lower nociceptive thresholds to thermal and
mechanical stimulations. They also had abnormal behavioural responses to the administration of exogenous
morphine and naloxone. Low dose of morphine (1 mg/kg, i.p.) produced a significant mechanical antinociception
in STOP null mice whereas it has no effect on wild-type mice. High concentration of naloxone (1 mg/kg) was
pronociceptive for both mice strain, a lower concentration (0.1 mg/kg) was found to increase the mean
mechanical nociceptive threshold only in the case of STOP null mice.
Conclusions-: Together, our data show that STOP null mice displayed elevated levels of endogenous morphine, as
well as an increase of morphine receptor affinity and density in brain. This was correlated with hypernociception
and impaired pharmacological sensitivity to mu opioid receptor ligands.
Background
Stable tubule-only polypeptides (STOP) are a family of
calmodulin binding and regulated microtubule asso-
ciated proteins (MAPs), encoded by a single gene in
mouse (Mtap6) [1,2] and human (MAP6) [3]. These
proteins have been firstly identified as microtubule sta-
bilizer [1,2,4] and play an important role in neuron
morphology, function [5,6] and migration [7,8]. STOP
proteins are also able to interact with actin cytoskele-
ton [9], with membranous compartments through
palmitoylation events [10] and are found in synaptoso-
mal fractions [11] indicating potential synaptic func-
tions. Accordingly, STOP null mice display alterations
of integrated brain functions compatible with some
symptoms of schizophrenia including neuroleptic-
sensitive behavioural abnormalities [11-13]. This mice
model exhibit increased basal locomotor activity dur-
ing the dark phase of the light/dark cycle, purposeless
and disorganized activity, severe social withdrawal and
nurturing defects [11,14]. In particularly, STOP null
mice have synaptic defects in the hippocampus well
correlated with a depletion of glutamatergic vesicle
resulting in a defective long-term potentiation (LTP)
and long-term depression (LTD) in the CA1 hippo-
campal area [11,15]. Hypersensitivity to acute stressful
situations, hyperlocomotion after amphetamine
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limbic system have also been described [12]. With
respect to the latter observation, electrically-evoked
dopamine release is selectively increased in the nucleus
accumbens of STOP null mice, whereas basal extracel-
lular dopamine levels are not changed in the striatum
or in the nucleus accumbens [11,12].
At the transcriptional level, STOP invalidation is asso-
ciated with a decrease of synaptophysin, VGlut1 (vesicu-
lar glutamate transporter-1), and spinophilin mRNAs in
the hippocampus and in the cerebellum [16]. Interest-
ingly, spinophilin, a dendritic spine-enriched scaffold
protein, is a modulator of opiate effects [17]. Thus, spi-
nophilin invalidation reduces sensitivity to the analgesic
effects of morphine but also the early development of
tolerance. Spinophilin appears to be associated with the
mu opioid receptor (MOR) in striatum and modulates
MOR both at the signaling and endocytosis levels. A sti-
mulation of MOR by morphine promotes a suppression
of MOR responsiveness [17].
Recent results suggested that endogenous morphine
(eM), whose structure is identical to that of morphine
isolated from poppies (for review see [18-20]), might
represent an interesting novel neuromodulator of brain
function. Although still under investigation, eM pre-
sence and synthesis has been characterized in numerous
mammalian cells [21-23] and tissues including brain
[24-26]. Morphine is particularly present in the hippo-
campus, striatum, cortex, hypothalamus, cerebellum,
and in key structures of the nociceptive system such as
the midbrain periaqueductal gray matter, nucleus raphe
magnus, rostroventral medulla complex and amygdala
[23,27-31]. In mammals, the biosynthesis of eM derives
at least from dopamine [32-34]. Thus, eM biosynthesis
and release were recently shown in the SH-SY5Y
human neuronal catecholamine-producing cell line
[23,32,35]. Endogenous morphine is likely involved in
different stress-modulating or pain-modulating mechan-
isms via binding to MORs which are expressed by
numerous cell types (e.g., neurons and immune cells)
[21,36-38]. Stimulation of these receptors leads to var-
ious effects, including analgesia but also modulation of
hormone synthesis and secretion (e.g., CRH), as well as
immunosupression [21,39]. Endogenous morphine,
which is present in nervous tissues and synthesized
from dopamine, may contribute to these behavioral
alterations since it is thought to play a role in normal
and pathological neurotransmission. To date, the func-
tional role of eM in the brain remains to be elucidated
and only few data are available regarding the presence
of morphine in cerebral areas with regards to its possi-
ble consequences on brain function.
The present study shows for the first time that STOP
null mice exhibit elevated levels of eM in different
macrostructures of the brain. The physiological conse-
quences of such high brain content of eM have been
investigated with regards to the potential associated
changes in morphine receptor (density and affinity) and
basal nociception.
Results
Endogenous levels of morphine in WT and STOP null
mice brains and sera
The presence and localization of eM and its derivatives
was examined in the encephalon of WT and STOP null
mice by immunohistochemistry. The 6D6 antibody has
previously been validated for the detection of morphine,
morphine-6-glucuronide (M6G), morphine-3-glucuro-
nide (M3G) and codeine [21]. A stronger immunoreac-
tivity for morphine-like compounds is observed for the
brain of STOP null mice compared to wild type mice
(Figure 1B and 1C) suggesting the presence of a higher
concentration of endogenous morphine. This immunor-
eactivity increase was global and no particular areas
were labeled in STOP null mice as compared to WT
animals. No immunoreactivity for eM or derivatives
was found in control experiments using morphine,
M6G, M3G and codeine-immunoadsorbed antibody
(Figure 1A and data not shown). In STOP null animals,
morphine-like immunolabel was found in different brain
areas implicated in nociception. Thus, morphine-like
immunoreactivity was found in neurons of the hippo-
campus CA2 area (arrows Figure 1Ca), hind limb pri-
mary somatosensory (S1HL) cortex (arrows Figure 1Cb)
and the cerebellum (immunolabel around Purkinje cell
bodies; arrow Figure 1Cc). Quantifications of morphine
levels in cerebellum (Figure 2), brainstem and remaining
parts of the brain (i.e., brain without cerebellum and
brainstem), as well as in spinal cord, were performed
using a morphine-specificE L I S Ak i t( s e em e t h o d s ) .
Quantification of eM present in WT animals shows the
presence of morphine in brain (0.25 ± 0.23 ng/g of tis-
sue; n = 13), cerebellum (1.13 ± 0.59 ng/g of tissue;
n = 13), brainstem (0.54 ± 0.44 ng/g of tissue; n = 13)
and spinal cord (0.05 ± 0.01 ng/g of tissue; n = 9; Figure
2). In STOP null mice, a statistically higher amount of
morphine per gram of tissue was found in the brain
(1.24 ± 0.69 ng/g of tissue; 483 ± 273% compared to
WT; p < 0.001; n = 10; mean +/- SD, Mann-Whitney
test using Bonferroni correction), cerebellum (3.03 ±
1.31 ng/g of tissue, 268 ± 116% compared to WT; p <
0.001; n = 10), brainstem (1.85 ± 0.7 ng/g of tissue, 341
± 130% compared to WT; p < 0.001; n = 10) and spinal
cord (0.13 ± 0.04 ng/g of tissue, 257 ± 93% compared to
WT; p < 0.01; n = 9; Figure 2).
In order to determine if the endogenous morphine
level in the blood is also altered, a quantification using a
morphine-specific ELISA was performed on the serum
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Page 2 of 14Figure 1 Immunodetection of morphine-like compounds in the brain of WT and STOP animals. A. Control experiment using anti-
morphine immunoadsorbed mouse monoclonal antibody (same incubation time as in B and C). B. Immunodetection of morphine-like
molecules in WT mouse brain. Sagittal slices were incubated with a mouse monoclonal anti-morphine antibody and visualized with an HRP-
conjugated donkey anti-mouse IgG. C. Immunodetection of morphine-like compounds in STOP null brain. Boxes indicated the areas of interest.
Ca-c panels correspond to the areas defined by the boxes. Arrows indicate eM immunoreactive neurons. S1HL, hind limb primary somatosensory
(S1HL) cortex.
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Page 3 of 14of STOP null (n = 8) and WT (n = 8) mice. Morphine
was undetectable in the serum of the two strains of
mice (i.e., under the detection limits; data not shown).
Together, these data indicate that STOP null mice
cerebral areas contain a significantly higher amount of
eM compared to WT animals.
To confirm the presence of morphine in brain extracts
of STOP and WT mice, LC-MS-MS analyses were per-
formed in SRM mode. The specific transition m/z 286.2
® 165.1 was used to qualify the presence of morphine.
The results obtained unambiguously confirm the pre-
s e n c eo fm o r p h i n ei nm o u s eb r a i no fb o t hW Ta n d
STOP null mice and are summarized in Figure 3 (3A
for standard morphine, 3B for WT mice and 3C for
STOP null animals).
Morphine binding in STOP null and WT mice
In order to determine specific Kd and Bmax values of
MORs, a saturation analysis was performed on a pool of
brain membrane of STOP null (5 brains pooled for 3
independent experiments) or WT mice (7 brains pooled
for 3 independent experiments) using [
3H]-morphine as
radioligand (Figure 4A). Analysis of saturation binding
curves yield an accurate estimation of Kd and Bmax
values (Figure 4A and 4B). In STOP null mice, the Kd
v a l u eo fM O R sw a s9 . 6±0 . 2n M( m e a n±S D ,n=3 ;
Figure 4D). This value was found to be statistically
l o w e rb y3 5 %c o m p a r e dt ow i l d - t y p em i c e( 1 4 . 6±0 . 2
nM, mean ± SD, n = 3, P < 0.0001, Student t-test). The
statistical analysis to compare variance (F-test; F = 1.0,
DFn = 2.0, Dfd = 2 and p = 1) assumes that variance
aren’t significantly different. The Bmax of morphine
opioid receptors determined for STOP null mice (43.8 ±
2.5 fmol/mg of protein, mean ± SD, n = 3; Figure 4C)
was higher (around 9%) than in wild-type mice (40.1 ±
3.5 fmol/mg of protein, mean ± SD, n = 3, P=0.0104,
t-test), showing the presence of a higher density of
MORs in the brain of the knock-down model. The sta-
tistical analysis to compare variance (F-test; F = 1.96,
DFn = 29, Dfd = 29 and p = 0.075) assumes that var-
iance aren’t significantly different. The linear-Scatchard
plot regression analysis leads to the same results.
Western blot analysis was performed in order to con-
firm that MOR protein expression is increased in STOP
null mice compared to wild type animals. In both
extracts, immunoreactivity was observed as a band at 55
kDa which is consistent with the expected molecular
weight of the mu opioid receptor (Figure 4E). MOR pro-
tein amount was found to increased by 12% in STOP
extracts (average n = 3) compared to wild type animals.
A control experiment using the secondary antibody
alone showed that no cross reactivity exists (Figure 4E).
Together, our data suggest that STOP deficiency lead
to a significant increase of MORs affinity and density in
whole brain compared to WT mice.
Mechanical and thermal nociception in WT and STOP null
mice
Mechanical and thermal nociception of STOP null ver-
sus WT animals were investigated with von Frey and
dynamic hot/cold plate assays, respectively.
STOP null mice display a significantly lower mechani-
cal nociceptive threshold compared to WT (Figure 5A).
The mean threshold was of 7.24 ± 0.22 g and of 4.31 ±
0.24 g for the WT littermates (n = 17) and STOP null
mice (n = 16; p < 0.001), respectively. Thermal nocicep-
tion was evaluated with hot (Figure 5B) and cold tem-
perature stimulations (Figure 5C) using dynamic ramps.
In the dynamic hot plate test (DHP: 1°C/minute from
30°C to 45°C), we found that STOP null mice (n = 16)
had a significantly lower nociceptive hot threshold
(Figure 5B1) with mean value of 40.25 ± 0.70°C com-
pared to WT mice (43.06 ± 0.47°C, n = 17; p < 0.01). In
good agreement with the result obtained in the hot
range, a significantly bigger mean cold threshold was
obtained for STOP null mice (5.61 ± 0.91°C; n = 18) in
comparison to WT mice (2.10 ± 0.71°C; n = 10; p <
0.05) when the mice were exposed to dynamic cold
plate test (DCP: 1°C/min; from 20°C to 0°C; Figure
5C1). It is interesting to note here that only 29.41% (10
mice out of 34) of WT mice but 68.75% (18 mice out of
32) of STOP null mice were producing jumps during
the DCP test. While counting the number of jumps in
the hot (from 30 to 42°C; Figure 5B2) and cold range
(from 20 to 2°C; Figure 5C2), we found that STOP null
Figure 2 Quantification of the morphine contents in different
mouse brain areas of WT and STOP null mice using a
morphine-specific ELISA. Amounts of endogenous morphine (ng)
present in the cerebellum, brainstem and the remaining brain
tissue, per gram of wet tissue. The values correspond to the
morphine amount determined for STOP null (n = 10 animals; white
bars) and WT (n = 13 animals; grey bars) mice in different cerebral
areas as indicated. For spinal cord, the values correspond to the
morphine amount determined for STOP null (n = 9 animals; white
bars) and WT (n = 9 animals; grey bars) mice. Amounts of eM in the
STOP null and WT groups were found statistically different (mean
+/- SD, Mann-Whitney test using Bonferroni correction; **: p < 0.01;
***: p < 0,001).
Charlet et al. Molecular Pain 2010, 6:96
http://www.molecularpain.com/content/6/1/96
Page 4 of 14mice were systematically hypernociceptive (heat: WT,
2.13 ± 0.85, STOP, 7.81 ± 1.91, p < 0.05; cold: WT, 1.85
± 1.22, STOP, 6.81 ± 1.97, p < 0.05). In summary,
STOP null mice displayed a significant higher sensibility
to thermal and mechanical stimuli than WT.
Morphine and naloxone modulation of mechanical
nociception
To evaluate the antinociceptive properties of morphine
on mechanical nociceptive threshold (von Frey fila-
ments), mice received a single subcutaneous injection of
morphine at a high (10 mg/kg) or low (1 mg/kg) con-
centration (Figure 6A). As expected, administration of
high dose (10 mg/kg) of morphine (Figure 6A1) induced
a significant increase of the mechanical threshold in
WT mice (from 7.50 ± 0.92 g to the cut-off value of 26
± 0 g; n = 6, p < 0.01) and STOP null mice (from 5.83
± 0.48 g to 21.17 ± 1.83 g; n = 6, p < 0.01). Interest-
ingly, injection of low dose (1 mg/kg) of morphine
(Figure 6A2) did not change the mean mechanical
threshold of WT animals (from 7.50 ± 0.50 g to 7.0 ±
0.45 g; n = 6, p > 0.05) whereas it significantly increased
the value of STOP null mice (from 5.00 ± 0.58 to 17.25
± 2.90; n = 6, p < 0.01). Saline subcutaneous injections
(vehicle of morphine) were without effect in both WT
and STOP null mice (data not shown; n = 6 per group).
In addition to morphine, we also characterized the
effects of high (1 mg/kg) and lower dose (0.1 mg/kg) of
naloxone, an antagonist of opioid receptors, on mechan-
ical nociceptive threshold (Figure 6B). Following the
injection of high dose of naloxone (Figure 6B1), the
mean threshold of the WT mice was decreased from
7.00 ± 0.52 g to 2.17 ± 0.40 g (n = 6; p < 0.01) and
from 4.17 ± 0.31 g to 1.45 ± 0.20 g (n = 6, p < 0.01) in
WT and STOP null mice, respectively. A slightly differ-
ent situation was observed while testing lower dose of
naloxone (Figure 6B2). In this case, no change was
observed in the mechanical threshold of WT mice (from
7.36 ± 0.20 g to 6.79 ± 0.88 g; n = 11, p > 0.05), whereas
in STOP null mice, naloxone significantly increase the
nociceptive threshold from 4.33 ± 0.37 g to 6.00 ±
0.53 g (n = 9, p < 0.05).
Discussion
The present study first indicated that the brain of STOP
null mice express high level of endogenous morphine
(eM) in comparison to WT littermates. MORs present
in the brains of STOP null mice were expressed at a
higher density and displayed a higher affinity for mor-
phine compared to WT mice. With respect to possible
consequences linked to altered eM brain content and
MORs alterations, we found that STOP null mice were
Figure 3 Characterization of morphine in mouse brain extracts.
Morphine qualification was performed in selected reaction
monitoring (SRM) mode with the following transitions: m/z 286.2 ®
165.1 (see also additional file 1). SRM trace of the specific transition
for morphine in A: standard samples of morphine (50, 100, 500 and
1000 fmol); B: WT brain animals and C: STOP null brain animals.
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Page 5 of 14hypersensitive to nociceptive stimuli [40] and showed
unusual nociceptive and motor responses following
morphine receptor ligand injections. Indeed, subcuta-
neous injections of low doses of morphine (1 mg/kg)
were ineffective in WT mice but produced a significant
antinociception and reduced locomotion in STOP null
mice. In line with this result but more unexpected, a
low dose of the antagonist naloxone was antinociceptive
in STOP null mice whereas it remained without effect
in WT. Altogether, these data lead to the hypothesis
that STOP null mice display an altered brain eM con-
tent and MOR pharmacology which might be
Figure 4 [
3H]-Morphine binding in WT and STOP null mice. A : Saturation analysis of [
3H]-morphine binding to the MORs in wild-type and
STOP null mice. Data are presented as means ± S.E.M. n = 3. B : Transformation of the data by linear regression_Scatchard plots. Data are
presented as means ± S.E.M. n = 3. C : Comparison of the Bmax values of MORs in wild-type and STOP null mice. D : Comparison of the Kd (C)
values of MORs in wild-type and STOP null mice. Data are presented as means ± S.E.M. n = 3, Statistical significance between STOP null versus
WT mice is indicated as follow: * p < 0.05, ** p < 0.01, *** p < 0.001 by Student t-test. E : Western blot analysis showing MOR immunolabel
present in 50 μg of brain proteins of wild-type and STOP null mice (n = 3). No cross reactivity was found for the secondary antibody used.
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phine receptor ligand administration or acute nocicep-
tive stimuli.
Elevated levels of endogenous morphine in the brain of
STOP null mice
Endogenous morphine has been previously described in
bovine, rat, monkey and dog brains (for review: [18,20]),
as well as in human neuroblastoma SH-SY5Y cells
[23,32]. We also found that eM is particularly strongly
expressed in the sensory motor cortex, hippocampus,
cerebellum and spinal cord. These areas express MORs
[41-44] thus suggesting that eM might be an important
homeostatic modulator of their respective functions. In
sharp contrast with the brain of WT animals, we found
that STOP null mice display higher levels of eM in gen-
eral. Since the biosynthesis of eM requires the presence
of dopamine [20,32-34], elevated levels of morphine may
result from an over production of dopamine. To support
this hypothesis, STOP null mice have been shown to
display dopamine hyper-reactivity in the limbic dopami-
nergic system and increased dopamine release in the
nucleus accumbens following electrical stimulation of
the medial forebrain bundle [11,12]. Alternatively, a pos-
sible uptake of circulating eM (or of its precursors) by
nerve cells and specific brain structures could also
explain why some dopamine-free brain regions express
eM. Further investigations will be required to fully
explain why higher eM levels are found in the brain and
Figure 5 Thermal Nociceptive thresholds and behaviors of WT
and STOP null mice. A. Mechanical von Frey thresholds of WT
(n = 17) and STOP null (n = 16) mice. B. Thermal hot nociceptive
thresholds (B1) and behaviors (B2: total number of jumps between 30
and 43°C) for WT (n = 16) and STOP null mice (n = 16). C. Thermal
cold nociceptive thresholds (C1) and behaviors (C2: total number of
jumps between 20 and 0°C) for WT (n = 10) and STOP null mice
(n = 18). Statistical significance between STOP null versus WT mice is
indicated as follow: * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 6 Effects of morphine and naloxone on mechanical
nociceptive threshold. A. Effects of a single subcutaneous
morphine injection, at 10 mg/kg (A1) and 1 mg/kg (A2), on
mechanical von Frey threshold for WT (n = 6) and STOP null mice
(n = 6). B. Effects of a single subcutaneous naloxone injection, at
1 mg/kg (B1) and 0.1 mg/kg (B2), on mechanical von Frey threshold
of WT (n = 6) and STOP null (n = 6) mice. Statistical significance is
indicated as follow: * p < 0.05, ** p < 0.01.
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might be linked to their atypical response to stress [12].
Elevated affinity and density of MORs in the brain of
STOP null mice
Our present study showed that STOP deficiency is asso-
ciated with an increase in the affinity and the density of
MORs in mice brain. These data, together with the high
levels of endogenous morphine found in STOP null
mice, raise several questions regarding the possible cel-
lular mechanisms that could be involved. Usually, upre-
gulation of receptors may results from an increased
receptor synthesis and decreased receptor degradation.
The increased affinity of opioid receptors has been pre-
viously shown to result from a decrease of phosphoryla-
tion, oligomerization and allosterism of opioid receptors
[45]. Because STOP proteins directly alter spinophilin
function and interaction with actin cytoskeleton [16,17],
this suggests the elevated morphine receptor affinity to
possibly result from an impaired receptor targeting at
the membrane and/or recycling. However, those changes
in morphine concentration could affect the affinity and
the density of morphine receptors [46,47]. We can
hypothesize that the occurrence of a higher affinity and
density of MORs in STOP null mice brain might explain
the effect of low morphine concentration (1 mg/kg)
compared to WT mice. Further experiments will be
required to identify the molecular/cellular mechanisms
involved in the case of STOP null mice.
Endogenous morphine and basal hypernociception of
STOP null mice
At this time, the physiological consequences of eM pre-
sence at various concentrations in bovine, rat, rodent,
monkey and dog brains remains to be better understood
[18,20,21]. Among the few evidence published in the lit-
erature indicating that eM might affect brain functions,
intracerebroventricular injections of an antibody raised
against the alkaloid morphine (i.e. immunoneutralization)
have suggested a role for eM in weakening memory pro-
cesses under stress conditions [48]. This result on memory
performance shows that stressful conditions are clearly
involving the endogenous morphine system. Because we
found higher eM content in the brain and spinal cord of
STOP null mice and since the function of nociceptive cen-
tral nervous system structures might be affected [27-31],
we characterized their nociception in comparison to their
WT littermates. STOP null mice do not display sponta-
neous nociceptive responses but they were hypersensitive
to acute mechanical and thermal nociceptive stimuli. Our
finding is in apparent contrast with the thermal hot hyper-
nociception seen after immunoneutralization of eM in
mice [28]. The reduction of paw withdrawal latency in the
hot-plate test at 52°C likely indicated that, in basal
condition, an eM-dependent antinociceptive tonic control
was present. It is interesting to note at this point that
treatment with various doses and durations of exogenous
morphine or derivatives has also ambivalent properties
being sometime hypoalgesic or hyperalgesic [49-51]. It
suggests that abnormal eM levels might be the substrate
for this hypernociception in STOP null mice. We cannot
fully explain at this stage why STOP null mice are hyper-
responsive to thermal and mechanical nociceptive stimuli,
but we can propose that the high levels of eM seen in the
spinal cord and brain of STOP null mice profoundly alters
the pharmacology and the function of opioid receptors.
Alternatively, the presence of high eM may be a compen-
satory mechanism to preserve a minimal opioidergic anti-
nociception despite major defects in the trafficking and/or
properties of opioid receptors resulting from the STOP
deletion. In good agreement with this proposal, STOP
invalidation was shown to decrease the mRNA levels of a
dendritic spine-enriched scaffold protein named spinophi-
lin [16]. Further experiments will be required to confirm
this hypothesis, but the behavioral consequences of exo-
genous morphine and naloxone administration strongly
support this proposal.
Effects of opioid receptor ligands on nociception
Two different concentrations of morphine have been
tested on nociception. In STOP null mice, it seems that
over-expression of eM in their brain is not associated
with decrease in morphine-sensitivity. In the contrary,
subcutaneous injection of a low dose of morphine (1
mg/kg, Figure 6A2) induces no analgesia in WT whereas
it produces a strong analgesia in STOP null mice. It
appears then that STOP null mice are either hypersensi-
tive to exogenous morphine or, alternatively, may bene-
fit from the existing basal eM concentrations to reach
an analgesic efficacy after low s.c. injection of morphine.
In line with these abnormal opioid responses to exogen-
ous opiates, injection of the mu-receptor antagonist
naloxone, at 0.1 mg/kg, induce a slight but significant
analgesia in STOP null mice but was without effect in
WT animals. Several articles report that low doses of
naloxone are able to enhance morphine analgesia
[52-54]. In our model, it is surprising to see that the
presence of high amount of eM in STOP null mice
whole encephalon and spinal cord is accompanied by a
basal hyper-nociception for all modalities tested com-
pared to WT. Such results may eventually be compared
to chronic morphine treatments, that are described to
induce tolerance and hyperalgesia [52-54].
Physiological consequences and potential clinical
significance of eM increase
In STOP null mice eM amounts present in brain
increase and both thermal and mechanical differences
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Page 8 of 14compared to control animals may be related to MOR
pharmacology abnormality. Our data suggest that an
increase of eM amount may directly affect the pharma-
cology of opioid receptor and thus their responsiveness.
In addition, it has been shown that a link exist between
STOP protein and MOR [16,17]. Thus, STOP disruption
may directly affect MOR pharmacology and thus endo-
genous and exogenous morphine binding and effects. In
the case of STOP null mice, such disruption is corre-
lated with a decrease of the nociceptive threshold.
A l t h o u g ht h eS T O Pf a m i l yp r o t e i ns e e m st ob eap r e -
dictable genetic factor that may be implicated in schizo-
phrenia, it is difficult to extrapolate our data to this
neuropathology. It is true, however, that these schizo-
phrenic patients exhibit abnormal nociception and this is
particularly problematic when they require surgery. Our
data suggest a possible implication of eM to finely tune
the efficiency of mu receptor ligands. A clinical study
aimed measuring the eM amounts together with nocicep-
tive thresholds in schizophrenic patients will certainly be
of significant interest in the near future in order to con-
firm the role of endogenous morphine in this pathology.
Conclusion
In conclusion, our data show that STOP null mice dis-
play elevated levels of endogenous morphine, as well as
an increase of MORs affinity and density, an observation
which is correlated with hypernociception and impaired
morphine receptor ligands sensitivity. The mechanistic
of eM implications in these processes have to be investi-
gated in future studies.
Materials and methods
Animals
STOP null mice were generated on a 50:50 BALBc/129
SvPas background as previously described [11], with
gene targeting being used to replace exon 1 of the
STOP gene with a non-functional construct. Experi-
ments were performed on 37 day-old STOP null male
mice and littermates, weighing 30 ± 3 g. Animals were
given free access to food and water, with a 12 h light-
dark cycle at a temperature of 22 ± 2°C. All experiments
were carried out in accordance with the European Com-
munity Council Directive (86/609/EEC) of November
24, 1986 and were approved by the regional ethics com-
mittee and French ministry of agriculture (license No.
67-116, to P.P.).
Drugs
Drugs were purchased from the following sources: mor-
phine hydrochloride (Sigma Aldrich, Saint Louis, USA),
Naloxone hydrochloride (Ascent Scientific, Princeton,
USA). Morphine hydrochloride and naloxone hydro-
chloride were dissolved in saline (NaCl 0.9%), for
subcutaneous injections. The effects of morphine and
naloxone on nociception were tested 20 min after the
injections. [N-methyl-
3H]-morphine was purchased from
American Radiolabeled Chemicals (80 Ci/mmol
St. Louis, USA).
Nociceptive tests
All nociceptive tests were preceded by at least 5 days of
habituation to handling and testing procedures, in order
to obtain stable basal values.
Mechanical nociceptive threshold measurement
The mechanical threshold leading to nociceptive hind-
paw withdrawal was determined using von Frey hairs
[55]. Briefly, mice were placed in clear Plexiglas® boxes
(7 cm × 9 cm × 7 cm) on an elevated mesh screen for a
habituation time of 15 min. Calibrated von Frey fila-
ments (Bioseb, Chaville, France) were then applied to
the plantar surface of each hindpaw in a series of
ascending forces (ranging between 0.4 and 26 g). Each
filament was tested five times per paw. The mechanical
threshold corresponded to the force of the filament
i n d u c i n gt h r e eo rm o r eh i n dpaw nociceptive withdra-
wals out of five consecutive trials.
Thermal nociception
Thermal nociceptive tests were made using a computer-
controlled dynamic hot and cold-plate (Bioseb, Vitrolles,
France) following our recently-described procedure [56].
The animals were placed in a Plexiglas cylinder (10 cm
diameter, 15 cm height) with a drilled cover for a habi-
tuation time of 15 min. For dynamic hot plate test
(DHP), animals were placed on the plate at 30 ± 0.1°C,
and the plate temperature increased up to 44°C, with a
1°C.min
-1 speed (r
2 = 1). For dynamic cold plate test
(DCP), animals were placed on the plate at 20 ± 0.1°C,
and the plate temperature was decreased down to 1°C,
with a 1°C.min
-1 speed (r
2 = 0.99). During each degree
i n t e r v a l ,f o rD H Po rD C P ,w ec o u n t e dt h en u m b e ro f
jumps displayed by the mouse. A cutoff value of 30
jumps was used to remove the mice from the test
(always over 43°C or below 2°C). The thermal nocicep-
tive threshold corresponded here to the temperature of
first jump for each mouse. The total number of jumps is
also given for hot (from 30°C to 43°C) and cold tem-
perature ramps (20°C to 2°C). Note that only mice exhi-
biting jumps in DHP/DCP tests were kept for analysis.
If all mice were producing jumps during the DHP test,
only a small percentage of them were having this beha-
vior in the DCP test.
Immunohistochemistry
The presence of endogenous morphine-like compounds
in mouse brain of STOP and WT animals was first
revealed via an immunohistochemistry approach on
sagittal brain slices (global morphine presence).
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Mice were deeply anesthetized by intraperitoneal injec-
tion of 0.1 ml of a 5.6% (w/v) pentobarbital sodium solu-
tion (CEVA Santé Animale, Libourne, France) and
perfused transcardially with 4% formaldehyde (EMS, Hat-
field, USA) in NaCl/Pi buffer (0.9% NaCl and 25 mM
sodium phosphate, pH 7.4) using a peristaltic pump.
Fixative solutions were chilled, and then injected for
10 min with a peristaltic pump at a flow rate of 10 ml/
min. The brain was quickly removed and incubated for 2
h at 4°C in the same fixative. Coronal and sagittal brain
sections (70 μm thick) were cut with a vibratome (Leica
VT 1000 S, Nanterre, France) and collected in Tris-buf-
fered saline (TBS: 50 mM Tris-HCl, 0.9% NaCl, pH 7.4).
Immunostaining
Immunostaining was performed on sections free-floating
in TBS as previously described [57]. Brain slices were
washed in TBS and incubated for 1 h in bovine serum
albumin (BSA; Sigma-Aldrich) diluted in TBS (3%, w/v)
in order to saturate nonspecific immunoreactive sites.
After six TBS washes of 5 min each, sections were incu-
bated overnight with a mouse monoclonal antibodies
(6D6, dilution 1:1000, Aviva System Biology, San Diego,
USA) raised against morphine-like compounds (mor-
phine, M3G, and M6G, based on supplier specifications
and our own experiments) [21,23].
After incubation with the primary antibody, brain
slices were washed six times with TBS (5 min) and incu-
bated with a horseradish-conjugated specific secondary
antisera (HRP-conjugated donkey anti-mouse IgG, dilu-
tion 1:400; P.A.R.I.S., Compiegne, France) for 2 h at
room temperature, followed by six TBS washes (5 min).
Several controls were carried out to assess antibody
specificity and nonspecific immunoreactivity. The pri-
mary antibody was omitted, and the secondary antibody
was tested individually or in a mixture in the presence
of tissue sections or cells. Controls for morphine immu-
noreactivity were carried out by incubating the antibody
with morphine (2 h, 25°C, 50:1, w/w) [23] prior to
immunocytochemistry experiments. Anti-morphine anti-
body was tested by ELISA in order to determine cross
reactivity with morphine, morphine-6-glucuronide
(M6G), morphine-6-glucuronide (M6G), dopamine,
adrenaline, noradrenaline and norlaudanosoline/tetrahy-
dropapaveroline, showing a specificity for morphine,
M6G and M3G. No cross reactivity was found for dopa-
mine, adrenaline, noradrenaline and norlaudanosoline/
tetrahydropapaveroline [21]. In order to assess whether
morphine binds to proteins nonspecifically, extracts
mouse hippocampus were submitted to Western blot
analysis (50 μg of RIPA-extract, SDS-PAGE 4-12% acry-
lamide Criterion XT precast gel 12%, sample buffer
60 mM Tris-HCl pH6.8, 2% SDS, 4 M Urea, 5% gly-
cerol, 1% b-mercaptoethanol, 5 min at 100°C); the
results show no anti-morphine antibody labeled proteins
in these extracts (data not shown).
Light microscopy immunocytochemistry studies
Peroxidase activity was observed after 20 min of incuba-
tion in a freshly prepared solution of 4-chloro 1-naphtol
(0.2 mg/ml) in TBS containing 0.006% (w/v) hydrogen
peroxide. After washing with TBS, the sections were
mounted in glycerol/TBS (1:1, v/v) before analysis with
a Leica DMRB microscope equipped with a digital cam-
era (Axiocam, Zeiss;objectives 10×, 20× and 40×). Brain
pictures were reconstructed using the Photostich 3.1
software (Canon).
Morphine-specific ELISA
Homogenized brain areas (cerebellum, brainstem and
brain) were sonicated at 4°C (3 × 10 sec) in water.
Extracts were centrifuged (30 min, 10.000 g,4 ° C ) ,a n d
the supernatant containing the intracellular material was
extracted with methanol (1:3, v:v final ratio). After cen-
trifugation (15 min, 10.000 g, 4°C), the supernatant was
dried with a SpeedVac evaporator (Thermo Fisher
Scientific, Brebières, France) and then dissolved in water
prior to ELISA analysis. For mouse serum analysis, ali-
quots of 40 μl were tested in duplicates.
The morphine-specific enzyme-linked immunosorbent
assay (ELISA) kit from Immunalysis Corporation
(Pomona, USA provided by AgriYork 400 Limited,
Pocklington, UK) was used for the quantification of
morphine present in brain tissue extracts (n = 6) [23].
The specificity of the test for morphine was confirmed
by testing different amounts of dopamine, adrenaline,
noradrenaline, norlaudanosoline/tetrahydropapaveroline,
morphine, M6G, M3G, and codeine (0.01 to 25 ng/ml,
data not shown). For all tests, morphine standards were
diluted in the appropriate buffer.
Gel electrophoresis and Western blot analysis
Proteins were separated on SDS-PAGE gradient gels
(4%-12% acrylamide; Criterion XT, BioRad) and electro-
transferred onto polyvinyldifluorene membranes (GE
Healthcare Bioscience, Sweden) [58]. In order to immu-
nodetect the mu receptors, 50 μg of brain RIPA-extracts
from WT and STOP null mice (n = 3). The MOR
receptor was detected using a goat anti-MOR1 antibody
(N-20; Santa Cruz Biotechnology, USA; dilution 1:1,000)
and revealed using HRP-conjugated anti-goat antisera
(Jackson immunoresearch, England; dilution 1:50,000)
and a Supersignal West Femto Kit (Pierce, Rockford,
USA). Apparent molecular weights were evaluated by
comparison with molecular weight standards (Bio-Rad).
Control experiments omitting the primary antibody con-
firmed the specificity of the label. Quantifications of the
intensity of immunoreactive bands were done using the
ImageJ software Version 1.43 http://rsbweb.nih.gov
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Few mass spectrometry (MS) methods have been
reported for the qualification and the quantification of
morphine and its glucuronide in biological sample
[59-61]. HILIC chromatography coupled to a triple
quadrupole mass spectrometry was used to develop a
method to accurately detect the presence of morphine
(MOR), morphine-3-glucuronide (M3G) and morphine-
6-glucuronide (M6G) in the selected reaction monitor-
ing (SRM). Identification of the compounds was based
on precursor ion, one selective fragment ions and their
relative retention times.
Prior to LC-MS-MS analysis, methanol extracted sam-
ples were dissolved in 0.1% trifluoroacetic acid in H2O
(v:v) and purified using an Äkta purifier HPLC system
(GE Healthcare Bioscience) as previously described [22].
Fractions corresponding to morphine were dried with a
SpeedVac evaporator prior to LC-MS-MS analysis.
LC separations were carried out with an Agilent LC
1100 binary pump, autosampler, vacuum degasser, and
column oven coupled with an Agilent 6410 Triple Quad
LC/MS (Agilent Technologies, Palo Alto, USA).
LC separations were carried out with an Agilent LC
1100 binary pump, autosampler, vacuum degasser, and
column oven coupled with an Agilent 6410 Triple Quad
LC/MS (Agilent Technologies, Palo Alto, USA). The dry
sample were resolvated in 10 μl of acetonitrile 70%, vor-
tex-mixed for 1 min and injected on an acrylamido-type
column (TSKgel Amide-80, TOSOH, Tokyo) at 25°C.
The solvent system consisted of 100% water, 0.15% for-
mic acid and 5 mM ammonium acetate (NH OAc; sol-
vent A) and 100% acetonitrile (solvent B). Elution was
performed at a flow rate of 220 μl/min with a 70-40%
linear gradient (solvent B) over the 8 first minutes, fol-
l o w e db ya8 0 %s t a g e( s o l v e n tB )o v e r2m i nb e f o r et h e
reconditioning of the column at 70% of solvent B. The
system was fully controlled by MassHunter software
(Agilent Technologies).
Electrospray ionization was achieved in the positive
mode with the spray voltage set at 4000 V. Nitrogen
w a su s e da sn e b u l i z e rg a sa n dn e b u l i z e rp r e s s u r ew a s
set at 20 psi with a source temperature of 100°C. Deso-
lvation gas (nitrogen) was heated to 350°C and delivered
at a flow rate of 10 L/min. Qualification was performed
in selected reaction monitoring (SRM) mode with the
following transitions: m/z 286.2 ® 165.1 for morphine.
The details of the optimized SRM parameters for Mor-
phine are shown in additional file 1.
Receptor Binding
Binding assay to brain membranes was conducted in a
96-well format. Animals were decapitated, brains were
rapidly removed and homogenized with 10 volumes
(w/v) of ice-cold 0.32 M sucrose using a Potter-
Elvehjem tissue grinder with a Teflon pestle. The homo-
genate was sonicated and then centrifuged at 4°C (10
min at 1000 g). The pellet was discarded and the super-
natant was centrifuged at 4°C for 20 min at 20,000 g.
The supernatant was decanted and the pellet was sus-
pended in ice-cold 50 mM Tris-HCl buffer (pH 7.4) and
sonicated. After 30 min at 4°C, the suspension was
r e s u s p e n d e da n dc e n t r i f u g e da t4 ° Cf o r2 0m i na t
20,000 g. The resulting pellet was further suspended in
Tris-HCl buffer (pH 7.4) and gently sonicated. Protein
concentrations were determined by the BCA method.
Proteins were stored at -70°C until used.
The binding assays were performed on membrane
extract (100 μg of protein in Tris-HCl buffer, pH 7.4)
from a pool of STOP mice (5 brains in the pool) or WT
mice (7 brains in the pool) in the presence of a concen-
tration of 0.1 nM to 50 nM of [
3H]-morphine ([N-
methyl-
3H]-morphine, 80 Ci/mmol, American Radiola-
beled Chemicals). Nonspecific binding was determined
i nt h ep r e s e n c eo f1 0μM morphine. Incubations were
performed at 37°C during 30 min. The binding was ter-
minated by rapid filtration of the mixture under vacuum
through Whatman GF/B filters presoaked for 30 min in
Tris-HCl buffer (pH 7.4). The filters were washed three
times with 0.2 ml of ice-cold Tris-HCl buffer (pH 7.4)
and transferred to 5 ml vials with 3 ml scintillation
liquid. Radioactivity was counted 24 h later by using a
Beckman scintillation counter. All experiments were
conducted in triplicate. Specific binding was determined
as the difference between radioligand bound in the
absence (total binding) and presence (nonspecific bind-
ing) of 10 μM morphine. The GraphPad Prism program
(GraphPad-Prism, San Diego, CA), was employed, with
a nonlinear curve fitting analysis, to fit the nM/mg of
proteins data to a saturation binding curve.
Statistical analysis
Morphine ELISA analysis
In order to assess if a difference of morphine amount
exist in brain tissues, determined morphine concentra-
tions were subjected to post hoc analysis using a Mann-
Whitney test. (STOP, n = 10; WT, n = 13). Statistical
data analysis was performed using MINITAB 13.20
(Minitab Inc.). For multiple comparisons, the signifi-
cance level was adjusted using Bonferroni correction.
The significant level was set at P < 0.001.
Morphine binding assay
These statistical processes were performed using the
GraphPad statistical software. Bmax and Kd values used
for statistics were calculated from the non-linear regres-
sion analysis which provides more reliable estimations
(GraphPad Prism Program). However, linear Scatchard
plot regression analyses were presented for rapid visual
interpretation of the data. Deviation from the model
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test and was never significant for all experiments. The r²
were always better than 0.96 in all cases. Statistical com-
parison between experimental conditions was assessed
by analysis of Student’s t-test after the confirmation that
t h ev a r i a n c ea r e n ’t significantly different. A probability
level of 0.05 or smaller was used to indicate statistical
significance.
Behavioral analysis
Data are expressed as mean ± SEM. Statistical analyses
were performed with KyPlot (KyensLab, Tokyo, Japan).
The Wilcoxon - Mann-Whitney U test for unpaired
data was used to compare non-parametric data from the
von Frey hair test or the hot/cold dynamic plate. For
the thermal nociceptive score as well as for the global
activity tests, Student’s t-test was used. The significant
level was set at p < 0.05.
Additional material
Additional file 1: Optimized SRM parameters for morphine.
Parameters used for the detection of morphine.
Abbreviations
DCP: dynamic cold plate test; DHP: dynamic hot plate test; ELISA: enzyme-
linked immunosorbent assay; eM: endogenous morphine; ESI: electrospray
ionization; MS/MS: mass spectrometry-mass spectrometry; M3G: morphine-3-
glucuronide; M6G: morphine-6-glucuronide; MOR: mu opioid receptor; SRM:
selected reaction monitoring; STOP: Stable tubule-only polypeptides; WT:
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